- $287.57m
- $589.94m
- $743.94m
- 54
- 80
- 55
- 67
C2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 353 | 446 | 532 | 638 | 744 |
Cost of Revenue | |||||
Gross Profit | 223 | 245 | 302 | 391 | 502 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 442 | 606 | 678 | 792 | 792 |
Operating Profit | -89.6 | -160 | -146 | -154 | -47.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -88.2 | -172 | -165 | -176 | -70.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -88.7 | -172 | -166 | -175 | -73.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -88.7 | -172 | -166 | -175 | -73.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -88.7 | -172 | -166 | -175 | -73.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.939 | -1.71 | -1.57 | -1.49 | -0.709 |